AURKA and neoplasm: Nonetheless, numerous mechanisms indirectly targeting this pathway, including the use of aurora kinase A (AURKA) and bromodomain and extra-terminal motif (BET) inhibitors, to name a few, provide viable therapeutic opportunities to decrease MYCN expression and reduce tumor volume (222).